Clinical Trials Details

NRG-GY026 (Endometrial)

A Phase II/III Study of Paclitaxel/Carboplatin alone or combined with either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab and Hyaluronidase-ZZXF (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Objective

Key eligibility: Stage IA-IVB, non-recurrent; chemo naive; HER2 + serous carcinoma or carcinosarcoma; within 8 weeks of primary signs/symptoms.

Stage I and II temporarily closed to accrual

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms